Exploiting Emerging Supramolecules as In Vivo Sequestrants to Induce Drug Reversal

Grants and Contracts Details

StatusActive
Effective start/end date3/5/246/30/24

Funding

  • Reversal Therapeutics Incorporated: $34,187.00